LEADER 01483nam  2200409Ia 450 
001 9910698732503321
005 20090421140021.0
035   $a(CKB)5470000002396532
035   $a(OCoLC)318914513
035   $a(EXLCZ)995470000002396532
100   $a20090421d2008      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGuidance for industry$b[electronic resource] $enucleic acid testing (NAT) to reduce the possible risk of parvovirus B19 transmission by plasma-derived products
210  1$aRockville, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research,$d[2008]
215   $ai, 5 pages $cdigital, PDF file
300   $aTitle from PDF title page (viewed on Apr. 21, 2009).
300   $a"Draft guidance."
300   $a"July 2008."
320   $aIncludes bibliographical references (pages 4-5).
517   $aGuidance for industry 
606   $aNucleic acids$xTesting
606   $aParvovirus infections$xPrevention
606   $aPlasma products
615  0$aNucleic acids$xTesting.
615  0$aParvovirus infections$xPrevention.
615  0$aPlasma products.
712 02$aCenter for Biologics Evaluation and Research (U.S.)
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910698732503321
996   $aGuidance for industry$93434577
997   $aUNINA